Delequamine

Delequamine
Clinical data
Other namesDMMIN; RS-15385; RS 15385; RS15385; RS 15385-197; RS-15385-197; RS15385-197
Drug classα2-Adrenergic receptor antagonist
Identifiers
  • (8aR,12aS,13aS)-3-methoxy-12-methylsulfonyl-5,6,8,8a,9,10,11,12a,13,13a-decahydroisoquinolino[2,1-g][1,6]naphthyridine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H26N2O3S
Molar mass350.48 g·mol−1
3D model (JSmol)
  • COC1=CC2=C(C=C1)[C@@H]3C[C@H]4[C@H](CCCN4S(=O)(=O)C)CN3CC2
  • InChI=1S/C18H26N2O3S/c1-23-15-5-6-16-13(10-15)7-9-19-12-14-4-3-8-20(24(2,21)22)17(14)11-18(16)19/h5-6,10,14,17-18H,3-4,7-9,11-12H2,1-2H3/t14-,17+,18+/m1/s1
  • Key:JKDBLHWERQWYKF-JLSDUUJJSA-N

Delequamine (INNTooltip International Nonproprietary Name; developmental code names RS-15385, RS-15385-197) is a potent and selective α2-adrenergic receptor antagonist which was under development for the treatment of erectile dysfunction and major depressive disorder but was never marketed.[1][2][3][4]

It is structurally related to the naturally occurring α2-adrenergic receptor antagonist yohimbine but has greater selectivity in comparison.[3][4] The drug has been found to affect sexual function and sleep in humans.[4]

Delequamine reached phase 3 clinical trials prior to the discontinuation of its development.[1] The drug was under development in the 1990s and its development was discontinued by 1999.[1] It was first described in the scientific literature by 1990.[5]

See also

References

  1. ^ a b c "Delequamine". AdisInsight. Springer Nature Switzerland AG. 22 September 1999. Retrieved 21 October 2024.
  2. ^ Ganellin CR, Triggle DJ (1996). Dictionary of Pharmacological Agents. Taylor & Francis. ISBN 978-0-412-46630-4. Retrieved 21 October 2024.
  3. ^ a b Maw GN (1999). "Pharmacological Therapy for the Treatment of Erectile Dysfunction". In Greenlee W, Hagmann WK, Plattner JJ, Robertson D, Trainor GL, Wong WW, Doherty AM (eds.). Annual Reports in Medicinal Chemistry. Annual Reports in Medicinal Chemistry. Vol. 34. Academic Press. p. 78. ISBN 978-0-08-058378-5. Retrieved 21 October 2024.
  4. ^ a b c Bancroft J (March 2000). "Effects of alpha-2 blockade on sexual response: experimental studies with Delequamine (RS15385)". International Journal of Impotence Research. 12 (S1): S64–S69. doi:10.1038/sj.ijir.3900507. PMID 10849567.
  5. ^ Clark RD, Spedding M, MacFarlane CB (1990). "RS-15385-197, a potent andselective alpha2-adrenoceptor antagonist". British Journal of Pharmacology. 99: 123P.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.